CHICAGO--(BUSINESS WIRE)--The Shareholders of Imagin Molecular Corporation (“IMGM”) have approved, through a consent of over 51% of shareholder vote, certain transactions wherein IMGM completed the acquisition of 3,100,000 Class B Preferred Shares of Positron Corporation which shares are convertible on a 1 for 100 basis into Positron common shares. This position marked to the current market price for Positron Corporation common shares has a value of in excess of $35 million. It is IMGM’s intention to hold the Positron Class B Preferred shares for investment purposes. The consideration for the exchange of the Positron investment position is the issuance of 310,000,000 common shares of IMGM to IMAGIN Diagnostic Centres, Inc. (IDC) a private Canadian company that is in the PET scanning business in Canada and a historical owner of the 3,100,000 Class B preferred block equity position. IMGM simultaneously announces its intent to build Cardiac Disease Reversal and Prevention Clinics across Canada and, after initial success, across the USA and globally. The new subsidiary will be named “Positron Cardiac CARE Clinics”. These clinics will base its imaging technology on Positron’s Attrius™ dedicated cardiac PET scanners.
